| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2014-01-21 |
| タイトル |
|
|
タイトル |
Comparison of efficacy and safety of 1-and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer |
| 言語 |
|
|
言語 |
eng |
| DOI |
|
|
|
関連識別子 |
https://doi.org/10.1007/s10147-012-0413-9 |
|
|
関連名称 |
10.1007/s10147-012-0413-9 |
| キーワード |
|
|
主題 |
Prostate cancer, Androgen deprivation therapy, Luteinizing hormone-releasing hormone agonist |
| 資源タイプ |
|
|
資源 |
http://purl.org/coar/resource_type/c_6501 |
|
タイプ |
journal article |
| 著者 |
Ishizuka, Osamu
Nishizawa, Osamu
Nishizawa, Shuji
Satoh, Tomoya
Wajiki, Masahisa
Kiyokawa, Hideo
Inoue, Yoshihiro
Kobayashi, Shinya
Mizusawa, Hiroya
Nakagawa, Tatsuo
|
| 信州大学研究者総覧へのリンク |
|
|
氏名 |
Ishizuka, Osamu |
|
URL |
http://soar-rd.shinshu-u.ac.jp/profile/ja.gmfaHekh.html |
| 信州大学研究者総覧へのリンク |
|
|
氏名 |
Nishizawa, Osamu |
|
URL |
http://soar-rd.shinshu-u.ac.jp/profile/ja.WeyeWmyU.html |
| 出版者 |
|
|
出版者 |
SPRINGER JAPAN KK |
| 引用 |
|
|
内容記述 |
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY. 18(3):524-530 (2013) |
| 書誌情報 |
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
巻 18,
号 3,
p. 524-530,
発行日 2013-06
|
| 抄録 |
|
|
内容記述 |
We compared the efficacy and safety of 1- and 3-month depots of the luteinizing hormone-releasing hormone (LH-RH) agonist goserelin acetate in prostate cancer patients. Patients were randomly assigned to the Direct Group that received the goserelin 3-month depot or the Switch Group that began with the 1-month depot for the first 3 months and then switched to the 3-month depot. All patients were co-administered the antiandrogen agent bicalutamide. Serum testosterone and prostate-specific antigen (PSA) levels and adverse events were recorded at weeks 4, 8, 12, and 24. Baseline testosterone levels in the Direct and Switch Groups were 4.98 and 5.07 ng/mL, respectively (P = 0.798). At each week, the levels in both groups were a parts per thousand currency sign0.50 ng/mL (castration level) with no significant differences between them. All of the patients in the Switch Group and 98.1 % in the Direct Group had achieved castration levels at week 12, and 100 % had achieved such levels at week 24. Baseline PSA levels in the Direct and Switch Groups were 52.37 and 46.72 ng/mL, respectively (P = 0.793). Levels in both groups dropped continuously, to about 1.0 ng/mL at week 24, with no significant differences between the groups at any time. Three patients in the Direct Group experienced adverse events that were attributed to the co-administered bicalutamide. There was no difference in the efficacy or safety between the 1- and 3-month depots of goserelin when given as initial prostate cancer treatment in combination with bicalutamide. Patients must be monitored for adverse events associated with bicalutamide. |
| 資源タイプ（コンテンツの種類） |
|
| ISSN |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
1341-9625 |
| 書誌レコードID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA11086579 |
| PubMed |
|
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
https://pubmed.ncbi.nlm.nih.gov/22552359 |
|
|
関連名称 |
22552359 |
| 権利 |
|
|
権利情報 |
The original publication is available at www.springerlink.com |
| 出版タイプ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
| WoS |
|
|
URL |
http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=ShinshuUniv&SrcApp=ShinshuUniv&DestLinkType=FullRecord&DestApp=WOS&KeyUT=000320456500025 |
Comparison_efficacy_safety_1-and 3-month_luteinizing.pdf (192.3 kB)
